iCardiac Technologies Inc.
This article was originally published in Start Up
Few issues are more nettlesome in drug development than the potential for a new drug to unleash rare but potentially lethal heart-rhythm irregularities. The industry has a glaring need for improved cardiac safety testing. iCardiac Technologies hopes to turn that need into a service business with its proprietary algorithms and advanced electrocardiogram biomarkers.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Do-It-Yourself Dermatology, features profiles of Therative and Xthetix. Plus these Start-Ups Across Health Care: iCardiac Technologies, Jenken Biosciences, Neovasc Medical, and Syntaxin.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.